scholarly journals Emerging Therapies in Myelofibrosis: Highlights From SOHO 2020

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Lisa Nodzon, PhD, ARNP, AOCNP
Keyword(s):  
Annual Meeting ◽  
Cancer Center ◽  
University Of Texas ◽  
New Therapies ◽  
Emerging Therapies ◽  
Md Anderson ◽  
The University

Lisa Nodzon, PhD, ARNP, AOCNP®, of Moffitt Cancer Center, highlights new therapies in development for myelofibrosis that were discussed by Srdan Verstovsek, MD, PhD, of The University of Texas MD Anderson Cancer Center, at the 2020 SOHO Annual Meeting.

scholarly journals Oral Hypomethylating Agents for Myelodysplastic Syndromes: Highlights From SOHO 2020

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Allyson Price, MPAS, PA-C
Keyword(s):  
Annual Meeting ◽  
Myelodysplastic Syndromes ◽  
Cancer Center ◽  
Hypomethylating Agents ◽  
University Of Texas ◽  
Md Anderson ◽  
The University

Allyson Price, MPAS, PA-C, of The University of Texas MD Anderson Cancer Center, highlights implications for advanced practitioners from the presentation at the 2020 SOHO Annual Meeting by Guillermo Garcia-Manero, MD, also from MD Anderson Cancer Center, on the development of oral hypomethylating agents for myelodysplastic syndromes.

scholarly journals Predicting Drug Response in Acute Lymphoblastic Leukemia: Highlights From SOHO 2020

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Allyson Price, MPAS, PA-C
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Annual Meeting ◽  
Drug Response ◽  
Lymphoblastic Leukemia ◽  
Cancer Center ◽  
Research Hospital ◽  
University Of Texas ◽  
Md Anderson ◽  
The University

Allyson Price, MPAS, PA-C, of The University of Texas MD Anderson Cancer Center, summarizes the session on the genomics of drug response in acute lymphoblastic leukemia presented by Jun J. Yang, PhD, of St. Jude’s Research Hospital, at the 2020 SOHO Annual Meeting.

scholarly journals Updates on Therapeutic Advancements in Relapsed or Refractory Multiple Myeloma: Highlights From SOHO 2020

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Lisa Nodzon, PhD, ARNP, AOCNP
Keyword(s):  
Multiple Myeloma ◽  
Annual Meeting ◽  
Cancer Center ◽  
Early Relapse ◽  
University Of Texas ◽  
Refractory Multiple Myeloma ◽  
Key Points ◽  
Md Anderson ◽  
The University

Lisa Nodzon, PhD, APRN, AOCNP®, of Moffitt Cancer Center, discusses key points on the management of early relapse in multiple myeloma, a session presented at the 2020 SOHO Annual Meeting by Robert Z. Orlowski, MD, PhD, of The University of Texas MD Anderson Cancer Center.

Program development of a preceptor bootcamp for operational pharmacy preceptors

2020 ◽  
Vol 77 (Supplement_1) ◽  
pp. S2-S7
Author(s):  
Devlin V Smith ◽  
Stefani Gautreaux ◽  
Alison M Gulbis ◽  
Jeffrey J Bruno ◽  
Kevin Garey ◽  
...  
Keyword(s):  
Survey Methodology ◽  
Medical Center ◽  
Academic Medical Center ◽  
Cancer Center ◽  
University Of Texas ◽  
Qualitative Feedback ◽  
Md Anderson ◽  
The University ◽  
Functional Areas ◽  
The Impact

Abstract Purpose To describe the development, design, and implementation of a pilot preceptor development bootcamp and feedback related to its feasibility and impact on operational pharmacy preceptors. Summary The University of Texas MD Anderson Cancer Center designed and implemented a pilot preceptor development bootcamp for operational staff pharmacists serving as residency preceptors for longitudinal weekend staffing experiences. A systematic, multipronged approach was taken to identify preceptor development gaps and design a full-day bootcamp curriculum. The resultant curriculum was comprised of content in major functional areas including using the 4 preceptor roles, documenting performance, giving and receiving feedback, and dealing with difficult situations or learners. The impact of the pilot preceptor development bootcamp was assessed using survey methodology and qualitative feedback from debrief discussions. Conclusion Implementation of a pilot preceptor bootcamp program addressing major areas of precepting skill was well received, resulted in positive feedback from operational pharmacy preceptors, and was feasible to implement at a large academic medical center.

scholarly journals 810. Resistance to the Minocycline-Rifampin-Chlorhexidine (MRCH) combination does not emerge in biofilms of Tetracycline and Rifampin resistant bacteria grown on MRCH catheters depleted below antimicrobially effective concentrations

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S448-S448
Author(s):  
Bahgat Gerges ◽  
Joel Rosenblatt ◽  
Y-Lan Truong ◽  
Ruth Reitzel ◽  
Ray Y Hachem ◽  
...  
Keyword(s):  
Bloodstream Infections ◽  
Cancer Center ◽  
Resistant Bacteria ◽  
Material Support ◽  
University Of Texas ◽  
Cook Medical ◽  
Catheter Technology ◽  
Md Anderson ◽  
The University

Abstract Background Central Line Associated Bloodstream Infections (CLABSIs) remain a significant medical problem for critically ill cancer patients who required catheters for extended durations. Minocycline (M) -Rifampin (R) loaded catheters have shown the greatest impact on reducing CLABSIs; however, there is a risk for developing antibiotic resistant organisms when exposed to catheters whose concentration becomes depleted below antimicrobially effective levels due to extended indwells. Chlorhexidine (CH) and M-R combination catheters (MRCH) have been proposed as a next generation catheter with improved performance. Here we studied whether bacteria that were Tetracycline and Rifampin resistant became resistant to MRCH when allowed to form biofilms on MRCH catheters depleted below antimicrobially effective MRCH concentrations. Methods Minimum inhibitory concentrations (MICs) of Tetracycline and/or Rifampin resistant stock isolates were measured by standard microbroth dilution methods. MRCH catheters were depleted to below antimicrobially effective concentrations by soaking in serum for 6 weeks. The resistant bacteria were then allowed to form biofilm for 24 hrs on the depleted catheters in broth. Following 24 hour incubation the adherent (breakthrough) bacteria were removed by sonication and MICs were remeasured. The same organisms grown on non-antimicrobial catheters were used as controls. Results MICs (ug/mL) of the organisms against each agent and the combination are tabulated below: MICs (ug/mL) of the organisms against each agent and the combination Conclusion The M and R resistant bacteria did not develop in vitro resistance to the MRCH combination after forming biofilms on MRCH catheters depleted below antimicrobially effective concentrations. Disclosures Joel Rosenblatt, PhD, Cook Medical (Shareholder, Other Financial or Material Support, Inventor of the MRCH catheter technology which is owned by the University of Texas MD Anderson Cancer Center and has been licensed to Cook Medical)Novel Anti-Infective Technologies (Shareholder, Other Financial or Material Support, Inventor of the MRCH catheter technology which is owned by the University of Texas MD Anderson Cancer Center and has been licensed to Cook Medical) Issam I. Raad, MD, Citius (Other Financial or Material Support, Ownership interest)Cook Medical (Grant/Research Support)Inventive Protocol (Other Financial or Material Support, Ownership interest)Novel Anti-Infective Technologies (Shareholder, Other Financial or Material Support, Ownership interest)

Sign in / Sign up

Export Citation Format

Share Document